U.S.: do not brew Merck hepatitis tablet with HIV drugs

<p>WASHINGTON (Reuters) – U.S. drug regulators are changing a tag for <span>Merck Co Inc</span>‘s recently authorized <span>Victrelis</span> diagnosis for hepatitis C to uncover it should not be taken with some widely used <span>HIV medicines</span>.</p>
<p> “Co-administration (of a dual drugs) … is not endorsed during this time given of a probability of shortening a efficacy of a medicines, needing a volume of HCV (<span>hepatitis C virus</span>) or <span>HIV</span> … in a blood to increase,” a <span>U.S. Food and Drug Administration</span> pronounced on Thursday.</p>
<p> The <span>FDA</span> and Merck initial warned about a emanate in Feb formed on a formula of a <span>drug interaction</span> study, though a tag change could serve tighten sales of Victrelis.</p>
<p> Victrelis, authorized final May, attacks a ...